Vital Therapies Inc (NASDAQ:VTL) has been assigned a consensus rating of “Hold” from the seven research firms that are covering the company, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a hold recommendation. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $6.00.

VTL has been the subject of several research reports. Cantor Fitzgerald set a $18.00 price target on Vital Therapies and gave the company a “buy” rating in a report on Sunday, September 9th. BidaskClub downgraded Vital Therapies from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 16th. William Blair reaffirmed a “buy” rating on shares of Vital Therapies in a report on Sunday, August 12th. ValuEngine downgraded Vital Therapies from a “buy” rating to a “hold” rating in a report on Wednesday, September 12th. Finally, Zacks Investment Research downgraded Vital Therapies from a “buy” rating to a “hold” rating in a report on Saturday.

In related news, Director Muneer A. Satter sold 11,382,277 shares of the business’s stock in a transaction dated Monday, September 17th. The stock was sold at an average price of $0.36, for a total value of $4,097,619.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Muneer A. Satter sold 447,500 shares of the business’s stock in a transaction dated Friday, September 14th. The shares were sold at an average price of $0.36, for a total value of $161,100.00. The disclosure for this sale can be found here. Insiders have sold 11,929,271 shares of company stock valued at $4,292,912 in the last three months. Insiders own 33.90% of the company’s stock.

A number of hedge funds have recently bought and sold shares of VTL. Quantitative Systematic Strategies LLC bought a new position in Vital Therapies in the second quarter valued at about $139,000. Rhumbline Advisers bought a new position in Vital Therapies in the second quarter valued at about $183,000. TD Asset Management Inc. grew its position in Vital Therapies by 50.2% in the second quarter. TD Asset Management Inc. now owns 36,344 shares of the company’s stock valued at $249,000 after acquiring an additional 12,144 shares during the last quarter. Schwab Charles Investment Management Inc. bought a new position in Vital Therapies in the second quarter valued at about $388,000. Finally, Northern Trust Corp grew its position in Vital Therapies by 12.0% in the first quarter. Northern Trust Corp now owns 83,688 shares of the company’s stock valued at $569,000 after acquiring an additional 8,993 shares during the last quarter. 21.35% of the stock is owned by institutional investors and hedge funds.

Vital Therapies stock traded down $0.02 during mid-day trading on Wednesday, hitting $0.29. 2,151,497 shares of the company’s stock traded hands, compared to its average volume of 1,962,438. Vital Therapies has a fifty-two week low of $0.23 and a fifty-two week high of $9.75. The company has a market capitalization of $13.21 million, a price-to-earnings ratio of -0.22 and a beta of 3.52.

About Vital Therapies

Vital Therapies, Inc, a biotherapeutic company, focuses on developing and commercializing a cell-based therapy for the treatment of acute forms of liver failure in the United States. Its product candidate is the ELAD system, an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials helps in enhancing the rates of survival in patients with acute forms of liver failure.

Read More: What does earnings per share mean?

Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.